Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne
Clin Mol Hepatol. 2023;29(Suppl):S157-S170.   Published online 2022 Nov 22     DOI: https://doi.org/10.3350/cmh.2022.0348
Citations to this article as recorded by Crossref logo
The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area
Chung‐Feng Huang, Po‐Cheng Liang, Pei‐Chien Tsai, Yu‐Ju Wei, Ching‐I Huang, Chih‐Wen Wang, Tyng‐Yuan Jang, Ming‐Lun Yeh, Po‐Yao Hsu, Ming‐Yen Hsieh, Yi‐Hung Lin, Chia‐Yen Dai, Wan‐Long Chuang, Jee‐Fu Huang, Ming‐Lung Yu
Journal of Gastroenterology and Hepatology.2024; 39(1): 193.     CrossRef
Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis
Chung‐Feng Huang, Po‐Cheng Liang, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Yao Hsu, Pei‐Chien Tsai, Yu‐Ju Wei, Ming‐Lun Yeh, Ming‐Yen Hsieh, Yi‐Hung Lin, Chao‐Kuan Huang, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu
The Kaohsiung Journal of Medical Sciences.2024; 40(4): 374.     CrossRef
The Portal Venous Pulsatility Index and Main Portal Vein Diameter as Surrogate Markers for Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Metabolic-Dysfunction-Associated Steatotic Liver Disease
Jaejun Lee, Seungmyeon Choi, Seong-Hyun Cho, Hyun Yang, Pil-Soo Sung, Si-Hyun Bae
Diagnostics.2024; 14(4): 393.     CrossRef
Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
Sang Yi Moon, Yang Hyun Baek, Se Young Jang, Dae Won Jun, Ki Tae Yoon, Young Youn Cho, Hoon Gil Jo, Ae Jeong Jo
Gut and Liver.2024; 18(2): 283.     CrossRef
Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet’s disease
Hye Kyung Hyun, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
European Journal of Gastroenterology & Hepatology.2024; 36(4): 445.     CrossRef
Evolutive Models, Algorithms and Predictive Parameters for the Progression of Hepatic Steatosis
Marinela Sînziana Tudor, Veronica Gheorman, Georgiana-Mihaela Simeanu, Adrian Dobrinescu, Vlad Pădureanu, Venera Cristina Dinescu, Mircea-Cătălin Forțofoiu
Metabolites.2024; 14(4): 198.     CrossRef
Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients
David Pérez Compte, Lucas Etourneau, Anne-Marie Hesse, Alexandra Kraut, Justine Barthelon, Nathalie Sturm, Hélène Borges, Salomé Biennier, Marie Courçon, Marc de Saint Loup, Victoria Mignot, Charlotte Costentin, Thomas Burger, Yohann Couté, Christophe Bru
Biomarker Research.2024;[Epub]     CrossRef
Aspartate Aminotransferase to Platelet Ratio Index (APRI) as a Predictor of Metabolic Syndrome (MetS) Development in Individuals With Type 2 Diabetes Mellitus
Amir Jalisi, Rijad Jahić, Avdo Kurtović, Miralem Đešević, Azra Husić-Selimović, Enisa Hodžić, Edina Lazović Salčin, Orhan Lepara, Almir Fajkić
Cureus.2024;[Epub]     CrossRef
Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
Mohammadjavad Sotoudeheian
Protein & Peptide Letters.2024; 31(4): 290.     CrossRef
Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study
Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon
American Journal of Gastroenterology.2024;[Epub]     CrossRef
Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
Maamon Basheer, Mohamed Naffaa, Nimer Assy
Clinical and Molecular Hepatology.2023; 29(2): 398.     CrossRef
Liver fibrosis markers and all cause mortality in people with type 2 diabetes: A population based study (The Ayrshire Diabetes Outcomes Cohort (ADOC) Study)
Andrew Collier, Christopher Curran, Lyall Cameron, Sarah H. Wild, Christopher D. Byrne
Diabetes, Obesity and Metabolism.2023; 25(9): 2659.     CrossRef
Identification of individuals at risk of hepatocellular carcinoma: screening for clinically significant liver fibrosis in patients with T2DM
Tina Reinson, Ryan M Buchanan, Christopher D Byrne
Expert Review of Endocrinology & Metabolism.2023; 18(5): 355.     CrossRef
Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
Lucy Petagine, Mohammed Gulrez Zariwala, Vinood B Patel
World Journal of Gastroenterology.2023; 29(32): 4831.     CrossRef
Us Fda Public Meeting: Identification of Concepts and Terminology for Multicomponent Biomarkers
Abena S Agyeman, Abbas Bandukwala, Khaled Bouri, Jessica Hawes, Daniel M Krainak, Samir Lababidi, William B Mattes, Elena V Mishina, Phillip Turfle, Sue-Jane Wang, Theresa Thekkudan
Biomarkers in Medicine.2023; 17(11): 523.     CrossRef
The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review
Teodora Biciusca, Sorina Ionelia Stan, Mara Amalia Balteanu, Ramona Cioboata, Alice Elena Ghenea, Suzana Danoiu, Ana-Maria Bumbea, Viorel Biciusca
Diagnostics.2023; 13(21): 3316.     CrossRef
Novel noninvasive indices for the assessment of liver fibrosis in primary biliary cholangitis
Yan Li, Meng-Jun Zhang, Xue-Hong Wang, Su-Hua Li
Biomedical Reports.2023;[Epub]     CrossRef